Repligen Corporation
NASDAQ:RGENMedical - Instruments & Supplies
-$3.66 today
- Market cap
- $11.04B
- Beta
- 1.08
- P/E (TTM)
- 142.4
- EPS (TTM)
- $0.91
Volume 1.30M
Average 1.08M
RGEN Total Non-current Liabilities
All obligations due after more than one year.
Repligen CorporationNASDAQ: RGEN
Total Non-current Liabilities · Q2 FY2026 · quarter ended Jun 2026
Total non-current liabilities broadly unchanged from a year ago
Total non-current liabilities stood at $705.49M at the end of Q2 FY2026, down 1.6% from a year earlier and up 0.9% from the prior quarter. Over 3 fiscal years it compounded at +48.4% a year.
Context
- Total non-current liabilities amounted to 23.9% of total assets at the end of Q2 FY2026, down 0.8 pp from a year earlier.
- Total non-current liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether total non-current liabilities keeps falling in the next quarterly balance sheet after a -1.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 707.74M USD
- Year-over-year change
- -3.1%
- 4-year CAGR
- +32.0%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 707.74M | -3.1% |
| FY2024 | 2024-12-31 | 730.16M | +4.1% |
| FY2023 | 2023-12-31 | 701.4M | +223.7% |
| FY2022 | 2022-12-31 | 216.7M | -7.0% |
| FY2021 | 2021-12-31 | 233.03M | — |
Total Non-current Liabilities vs competitors
How RGEN compares with its peers on the latest reported figures
- RGEN's Jun 2026 total non-current liabilities of $705.49M is the 6th highest of the 9 companies compared; the peer median is $2.03B.
- Its year-over-year change of -1.6% is the 5th highest of 9, against a peer median of -3.8%.
- Total non-current liabilities amounts to 23.9% of total assets for RGEN, versus a peer median of 32.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $45.3B | +22.5% | +5.0% | 39.7% | |
| Jun 2026 | $4.58B | +17.1% | -11.3% | 39.5% | |
| Jul 2026 | $4.32B | +8.9% | +2.6% | 30.9% | |
| Jun 2026 | $2.12B | -16.5% | -7.7% | 20.6% | |
| Jun 2026 | $1.95B | +63.9% | +2.8% | 33.1% | |
| Jun 2026 | $705.49M | -1.6% | +48.4% | 23.9% | |
| Jun 2026 | $209.74M | -41.6% | -34.7% | 34.7% | |
| Sep 2026 | $109.86M | -73.6% | -9.2% | 4.2% | |
| Mar 2026 | $10.42M | -29.5% | -35.7% | 2.6% | |
| Peer median (excluding RGEN) | $2.03B | -3.8% | -8.5% | 32.0% | |
Competitors are the stored peer set for RGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 603.81M | 523.46M | 751.32M | 757.36M | 566.02M |
| Short-term Investments | 0 | 100.3M | 0 | 0 | 201.61M |
| Net Receivables | 117.42M | 116.25M | 124.16M | 134.12M | 158.59M |
| Inventory | 184.49M | 238.28M | 202.32M | 142.96M | 170.46M |
| Other Current Assets | 19.27M | 17.41M | 19.92M | 20.6M | 27.14M |
| Total Current Assets | 931.68M | 998.12M | 1.11B | 1.07B | 1.14B |
| Property, Plant & Equipment (Net) | 226.52M | 315.7M | 322.96M | 333.12M | 306.15M |
| Goodwill | 860.36M | 855.51M | 987.12M | 1.03B | 1.11B |
| Intangible Assets | 337.27M | 360.62M | 406.96M | 397.9M | 386.15M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 1.9M | 840K | 1.53M | 749K | 694K |
| Other Non-current Assets | 615K | 815K | 1.28M | 868K | 4.91M |
| Total Non-current Assets | 1.43B | 1.53B | 1.72B | 1.76B | 1.81B |
| Total Assets | 2.36B | 2.53B | 2.83B | 2.83B | 2.95B |
| Account Payables | 36.2M | 27.55M | 19.56M | 32.13M | 30.01M |
| Short-term Debt | 255.26M | 284.62M | 69.45M | 0 | 21.56M |
| Tax Payables | 4.98M | 2.46M | 6.81M | 0 | 0 |
| Deferred Revenue | 14.68M | 19.28M | 17.07M | 13.24M | 14.61M |
| Other Current Liabilities | 42.15M | 47.47M | 29.64M | 49.29M | 25.92M |
| Total Current Liabilities | 375.26M | 404.2M | 164.94M | 126.79M | 135.83M |
| Long-term Debt | 0 | 0 | 510.14M | 525.57M | 542.21M |
| Deferred Tax Liabilities | 33.48M | 23M | 39.32M | 22.78M | 22.5M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 1.54M |
| Other Non-current Liabilities | 97.05M | 62.32M | 25.35M | 36.24M | 15.32M |
| Total Non-current Liabilities | 233.03M | 216.7M | 701.4M | 730.16M | 707.74M |
| Total Liabilities | 608.29M | 620.9M | 866.34M | 856.95M | 843.57M |
| Common Stock | 553K | 556K | 558K | 561K | 563K |
| Retained Earnings | 194.06M | 397.27M | 432.87M | 407.35M | 456.25M |
| Accumulated OCI | (16.89M) | (34.39M) | (37.81M) | (52.53M) | (2.53M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 1.75B | 1.91B | 1.96B | 1.97B | 2.11B |
| Total Debt | 366.05M | 422.96M | 711.8M | 686.25M | 689.95M |
| Net Debt | (237.76M) | (100.5M) | (39.52M) | (71.11M) | 123.93M |
Repligen Corporation
NASDAQ:RGEN
Intrinsic Alpha fair value
Locked
Current Price
$172.67
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.